Jacobio Pharmaceuticals
1167 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Jacobio Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | SHP2Small molecule | Non-Small Cell Lung Cancer | |
| Phase 2 | BET bromodomain proteins (e.g. BRD4)Small molecule | Non-Small Cell Lung CancerRheumatoid ArthritisMyelofibrosis | |
| Phase 1/2 | KRAS MutantSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (3)
March 2027 (1)
What to watch
June 2027 (1)
August 2027 (1)
What to watch
2028 (2)
2029 (2)
September 2029 (1)
What to watch
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $6.3M | $13M | $149M | $8.1M | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $22M | $46M | $199M | — | report ↗ |
Jacobio Pharmaceuticals reported 2024 annual revenue of $22.27M, R&D spend of $45.93M, and cash and equivalents of $198.68M. Net income or loss was not disclosed in the provided figures, and no year-over-year comparison was available.
The company highlighted key clinical progress, including the submission of an NDA for its KRAS G12C inhibitor glecirasib in second-line and above non-small cell lung cancer, with expected approval in the first half of 2025, and an August 2024 licensing agreement with Allist covering China rights to glecirasib and the SHP2 inhibitor sitneprotafib. Additional updates included ongoing Phase III trials, IND approvals for early-stage candidates JAB-23E73 and JAB-30355, and completed dose escalation for JAB-8263.